The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations
Corresponding Author
Raul Martínez-Fernández MD
CINAC-Hospital Universitario HM Puerta del Sur, CEU-San Pablo University, Madrid, Spain
Correspondence to: Dr. Raul Martínez-Fernández, CINAC-HM Puerta del Sur, Avenida Carlos V 70, Móstoles, 28937, Madrid, Spain; E-mail: [email protected]Search for more papers by this authorEmmanuelle Schmitt MSc
Movement Disorders Unit, Department of Psychiatry and Neurology, CHU de Grenoble, Université de Grenoble Alpes and Grenoble Institut des Neurosciences, INSERM U386, Grenoble, France
Search for more papers by this authorPablo Martinez-Martin MD, PhD
National Center of Epidemiology, Carlos III Institute of Health and CIBERNED, Madrid, Spain
Search for more papers by this authorPaul Krack MD, PhD
Neurology Division, Department of Clinical Neurosciences, University Hospital of Geneva, Geneva, Switzerland
Search for more papers by this authorCorresponding Author
Raul Martínez-Fernández MD
CINAC-Hospital Universitario HM Puerta del Sur, CEU-San Pablo University, Madrid, Spain
Correspondence to: Dr. Raul Martínez-Fernández, CINAC-HM Puerta del Sur, Avenida Carlos V 70, Móstoles, 28937, Madrid, Spain; E-mail: [email protected]Search for more papers by this authorEmmanuelle Schmitt MSc
Movement Disorders Unit, Department of Psychiatry and Neurology, CHU de Grenoble, Université de Grenoble Alpes and Grenoble Institut des Neurosciences, INSERM U386, Grenoble, France
Search for more papers by this authorPablo Martinez-Martin MD, PhD
National Center of Epidemiology, Carlos III Institute of Health and CIBERNED, Madrid, Spain
Search for more papers by this authorPaul Krack MD, PhD
Neurology Division, Department of Clinical Neurosciences, University Hospital of Geneva, Geneva, Switzerland
Search for more papers by this authorThis article was published online on 19 July 2016. After online publication, revisions were made to the author line and text. This notice is included in the online and print versions to indicate that both have been corrected on 29 July 2016.
Relevant conflicts of interest/financial disclosures: R.M.-F. has received honorarium from UCB for speaking in a symposium.
Full financial disclosures and author roles may be found in the online version of this article.
ABSTRACT
Only a few years after the introduction of levodopa, the first descriptions of motor fluctuations and dyskinesia related to dopaminergic therapy appeared. In PD, attention turned to their management, that had dampened the euphoria of the “levodopa miracle.” It soon became clear that neuropsychiatric, autonomic, and sensory features also tend to develop fluctuations after chronic exposure to l-dopa. The diversity of fluctuating nonmotor symptoms, their largely subjective nature, coupled with a frequent lack of insight led to difficulties in identification and quantification. This may explain why, despite the high impact of nonmotor symptoms on patient autonomy and quality of life, evaluation of nonmotor fluctuations is not part of clinical routine. In view of the lack of specific validated assessment tools, detailed anamnesis should ideally be coupled with an evaluation in both ON and OFF drug conditions. The mechanisms of nonmotor fluctuations are not well understood. It is thought that they share dopaminergic presynaptic pharmacokinetic and postsynaptic pharmacodynamic mechanisms with the classical motor complications, but involve different neural pathways. Although symptoms fluctuate with dopaminergic treatment, serotonine and norepinephrine denervation, as well as interactions between neurotransmitter systems, probably contribute to their diversity. The lack of validated tools for assessment of these phenomena explains the almost complete absence of treatment studies. Management, largely resulting from expert opinion, includes psychiatric follow-up, nondopaminergic drugs, and advanced dopaminergic treatment, including drug delivery pumps and DBS. This review aims to provide a starting point for the understanding, diagnosis, and management of nonmotor fluctuations. © 2016 International Parkinson and Movement Disorder Society
References
- 1 Parkinson J. An essay on the shaking palsy. London: Sherwood Neely & Jones; 1817.
- 2 Fahn S. The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord 2015; 30: 4–18.
- 3 Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69: 308–312.
- 4 Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235–245.
- 5 Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007; 22: 1623–1629.
- 6 Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 2001; 16: 507–510.
- 7 Martinez-Martin P. Nonmotor symptoms and health-related quality of life in early Parkinson's disease. Mov Disord 2014; 29: 166–168.
- 8 Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham AM, Marsden CD. Mood swings associated with the ‘on-off’ phenomenon in Parkinson's disease. Psychol Med 1987; 17: 899–904.
- 9 Quinn NP. Classification of fluctuations in patients with Parkinson's disease. Neurology 1998; 51(2 Suppl 2): S25–S29.
- 10 Barbeau A. Long-term side-effects of levodopa. Lancet 1971; 1: 395.
- 11 Barbeau A. L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can Med Assoc J 1969; 101: 59–68.
- 12 Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969; 21: 343–354.
- 13 Marsden CD, Parkes JD. “On-off” effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1: 292–296.
- 14 Cantello R, Gilli M, Riccio A, Bergamasco B. Mood changes associated with “end-of-dose deterioration” in Parkinson's disease: a controlled study. J Neurol Neurosurg Psychiatry 1986; 49: 1182–1190.
- 15 Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain 1984; 107(Pt 2): 487–506.
- 16 Lees AJ. The on-off phenomenon. J Neurol Neurosurg Psychiatry 1989;Suppl: 29–37.
- 17 Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993; 43: 1459–1464.
- 18 Menza MA, Sage J, Marshall E, Cody R, Duvoisin R. Mood changes and “on-off” phenomena in Parkinson's disease. Mov Disord 1990; 5: 148–151.
- 19 Maricle RA, Nutt JG, Carter JH. Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings. Mov Disord 1995; 10: 329–332.
- 20 Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 1995; 45: 1757–1760.
- 21 Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408–413.
- 22 Muller B, Assmus J, Herlofson K, Larsen JP, Tysnes OB. Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson's disease. Parkinsonism Relat Disord 2013; 19: 1027–1032.
- 23 Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013; 80: 800–809.
- 24 Rieu I, Houeto JL, Pereira B, et al. Impact of mood and behavioral disorders on quality of life in Parkinson's disease. J Parkinsons Dis 2016; 6: 267–277.
- 25 Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 2004; 52: 784–788.
- 26 Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord 2015; 30: 121–127.
- 27 Beaulieu-Boire I, Lang AE. Behavioral effects of levodopa. Mov Disord 2015; 30: 90–102.
- 28 Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 2009; 24: 1561–1570.
- 29 Racette BA, Hartlein JM, Hershey T, Mink JW, Perlmutter JS, Black KJ. Clinical features and comorbidity of mood fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002; 14: 438–442.
- 30 Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005; 20: 726–733.
- 31 Bayulkem K, Lopez G. Nonmotor fluctuations in Parkinson's disease: clinical spectrum and classification. J Neurol Sci 2010; 289: 89–92.
- 32 Picillo M, Palladino R, Moccia M, et al. Gender and non motor fluctuations in Parkinson's disease: a prospective study. Parkinsonism Relat Disord 2016; 27: 89–92.
- 33 Witjas T, Kaphan E, Regis J, et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. Mov Disord 2007; 22: 1729–1734.
- 34 Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009; 24: 1468–1474.
- 35 Stacy MA, Murck H, Kroenke K. Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 57–61.
- 36 Ortega-Cubero S, Clavero P, Irurzun C, et al. Effect of deep brain stimulation of the subthalamic nucleus on non-motor fluctuations in Parkinson's disease: two-years' follow-up. Parkinsonism Relat Disord 2013; 19: 543–547.
- 37 Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464–474.
- 38 Hillen ME, Sage JI. Nonmotor fluctuations in patients with Parkinson's disease. Neurology 1996; 47: 1180–1183.
- 39 Gunal DI, Nurichalichi K, Tuncer N, Bekiroglu N, Aktan S. The clinical profile of nonmotor fluctuations in Parkinson's disease patients. Can J Neurol Sci 2002; 29: 61–64.
- 40 Seki M, Takahashi K, Uematsu D, et al. Clinical features and varieties of non-motor fluctuations in Parkinson's disease: a Japanese multicenter study. Parkinsonism Relat Disord 2013; 19: 104–108.
- 41 Brun L, Lefaucheur R, Fetter D, et al. Non-motor fluctuations in Parkinson's disease: prevalence, characteristics and management in a large cohort of parkinsonian outpatients. Clin Neurol Neurosurg 2014; 127: 93–96.
- 42 Storch A, Schneider CB, Klingelhofer L, et al. Quantitative assessment of non-motor fluctuations in Parkinson's disease using the Non-Motor Symptoms Scale (NMSS). J Neural Transm (Vienna) 2015; 122: 1673–1684.
- 43 Antonini A, Barone P, Marconi R, et al. The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. J Neurol 2012; 259: 2621–2631.
- 44 Zis P, Rizos A, Martinez-Martin P, et al. Non-motor symptoms profile and burden in drug naive versus long-term Parkinson's disease patients. J Parkinsons Dis 2014; 4: 541–547.
- 45 Obeso JA, Rodriguez-Oroz M, Marin C, et al. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 2004; 62(1 Suppl 1): S17–S30.
- 46 Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 1989; 39: 7–10; discussion, 9.
- 47 Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 2000; 23(10 Suppl): S109–S115.
- 48 Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5: 677–687.
- 49 Cilia R, Akpalu A, Sarfo FS, et al. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain 2014; 137: 2731–2742.
- 50 Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988; 334: 345–348.
- 51 Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013; 136: 2419–2431.
- 52 Stocchi F, Jenner P, Obeso JA. When do levodopa motor fluctuations first appear in Parkinson's disease? Eur Neurol 2010; 63: 257–266.
- 53 de la Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004; 127: 2747–2754.
- 54 Richard IH, Justus AW, Kurlan R. Relationship between mood and motor fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001; 13: 35–41.
- 55 Chaudhuri KR, Yates L, Martinez-Martin P. The non-motor symptom complex of Parkinson's disease: a comprehensive assessment is essential. Curr Neurol Neurosci Rep 2005; 5: 275–283.
- 56 Ossig C, Sippel D, Fauser M, et al. Assessment of non-motor fluctuations using a diary in advanced Parkinson's disease. J Parkinsons Dis 2016 May 31. doi: 10.3233/JPD-150764. [Epub ahead of print]
10.3233/JPD-150764 Google Scholar
- 57 Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013; 136: 1568–1577.
- 58 Defazio G, Berardelli A, Fabbrini G, et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol 2008; 65: 1191–1194.
- 59 Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006; 63: 1756–1760.
- 60 Brown P, Marsden CD. What do the basal ganglia do? Lancet 1998; 351: 1801–1804.
- 61 Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005; 128: 1314–1322.
- 62 Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord 2014; 29: 634–650.
- 63 Riedel O, Dodel R, Deuschl G, et al. Depression and care-dependency in Parkinson's disease: results from a nationwide study of 1449 outpatients. Parkinsonism Relat Disord 2012; 18: 598–601.
- 64 Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci 2006; 248: 151–157.
- 65 Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009; 24: 1641–1649.
- 66 Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011; 26: 399–406.
- 67 Friedenberg DL, Cummings JL. Parkinson's disease, depression, and the on-off phenomenon. Psychosomatics 1989; 30: 94–99.
- 68 Aarsland D, Bronnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 2009; 80: 928–930.
- 69 Dujardin K, Sockeel P, Carette AS, Delliaux M, Defebvre L. Assessing apathy in everyday clinical practice with the short-form Lille Apathy Rating Scale. Mov Disord 2013; 28: 2014–2019.
- 70 Santangelo G, Barone P, Cuoco S, et al. Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale. J Neurol 2014; 261: 2319–2328.
- 71 Sierra M, Carnicella S, Strafella AP, et al. Apathy and impulsive control disorders: yin & yang of dopamine dependent behaviors. J Parkinsons Dis 2015; 5: 625–636.
- 72 Pagonabarraga J, Martinez-Horta S, Fernandez de Bobadilla R, et al. Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. Mov Disord 2016; 31: 45–52.
- 73 Favier M, Duran T, Carcenac C, Drui G, Savasta M, Carnicella S. Pramipexole reverses Parkinson's disease-related motivational deficits in rats. Mov Disord 2014; 29: 912–920.
- 74 Drui G, Carnicella S, Carcenac C, et al. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease. Mol Psychiatry 2014; 19: 358–367.
- 75 Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 2015; 14: 518–531.
- 76 Bjorklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007; 30: 194–202.
- 77 Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010; 133: 1111–1127.
- 78 Maricle RA, Valentine RJ, Carter J, Nutt JG. Mood response to levodopa infusion in early Parkinson's disease. Neurology 1998; 50: 1890–1892.
- 79 Kulisevsky J, Avila A, Barbanoj M, Antonijoan R, Berthier ML, Gironell A. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 1996; 119(Pt 6): 2121–2132.
- 80 Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002; 125: 584–594.
- 81 Tang J, Strafella AP. The frontostriatal circuitry and behavioral complications in PD. Parkinsonism Relat Disord 2012; 18(Suppl 1): S104–S106.
- 82 Obeso JA, Rodriguez-Oroz MC, Benitez-Temino B, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord 2008; 23(Suppl 3): S548–S559.
- 83 Acquas E, Di Chiara G. Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J Neurochem 1992; 58: 1620–1625.
- 84 Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988; 85: 5274–5278.
- 85 Bodi N, Keri S, Nagy H, et al. Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain 2009; 132: 2385–2395.
- 86 Murray AM, Ryoo HL, Gurevich E, Joyce JN. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci U S A 1994; 91: 11271–11275.
- 87 Canales JJ, Graybiel AM. A measure of striatal function predicts motor stereotypy. Nat Neurosci 2000; 3: 377–383.
- 88 Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997; 278: 52–58.
- 89 Evans AH, Lawrence AD, Cresswell SA, Katzenschlager R, Lees AJ. Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward. Mov Disord 2010; 25: 867–876.
- 90 Cilia R, Siri C, Canesi M, et al. Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry 2014; 85: 311–318.
- 91 Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589–595.
- 92 Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005; 65: 1570–1574.
- 93 Stacy MA, Murck H, Kroenke K. Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 57–61.
- 94 Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006; 30: 1–23.
- 95 Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002; 67: 53–83.
- 96 Reijnders JS, Scholtissen B, Weber WE, Aalten P, Verhey FR, Leentjens AF. Neuroanatomical correlates of apathy in Parkinson's disease: a magnetic resonance imaging study using voxel-based morphometry. Mov Disord 2010; 25: 2318–2325.
- 97 Tinaz S, Courtney MG, Stern CE. Focal cortical and subcortical atrophy in early Parkinson's disease. Mov Disord 2011; 26: 436–441.
- 98 Feldmann A, Illes Z, Kosztolanyi P, et al. Morphometric changes of gray matter in Parkinson's disease with depression: a voxel-based morphometry study. Mov Disord 2008; 23: 42–46.
- 99 Matsui H, Nishinaka K, Oda M, et al. Depression in Parkinson's disease. Diffusion tensor imaging study. J Neurol 2007; 254: 1170–1173.
- 100 Li W, Liu J, Skidmore F, Liu Y, Tian J, Li K. White matter microstructure changes in the thalamus in Parkinson disease with depression: a diffusion tensor MR imaging study. AJNR Am J Neuroradiol 2010; 31: 1861–1866.
- 101 Kostic VS, Agosta F, Petrovic I, et al. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology 2010; 75: 857–863.
- 102 Kostic VS, Filippi M. Neuroanatomical correlates of depression and apathy in Parkinson's disease: magnetic resonance imaging studies. J Neurol Sci 2011; 310: 61–63.
- 103 Mayberg HS, Starkstein SE, Sadzot B, et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 1990; 28: 57–64.
- 104 Black KJ, Hershey T, Hartlein JM, Carl JL, Perlmutter JS. Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson's disease. Neuropsychopharmacology 2005; 30: 590–601.
- 105 Le Jeune F, Drapier D, Bourguignon A, et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 2009; 73: 1746–1751.
- 106 Torack RM, Morris JC. The association of ventral tegmental area histopathology with adult dementia. Arch Neurol 1988; 45: 497–501.
- 107 Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol 2009; 66: 167–172.
- 108 Jost WH. Autonomic dysfunctions in idiopathic Parkinson's disease. J Neurol 2003; 250(Suppl 1): I28–I30.
- 109 Goetz CG, Lutge W, Tanner CM. Autonomic dysfunction in Parkinson's disease. Neurology 1986; 36: 73–75.
- 110 Pursiainen V, Korpelainen JT, Haapaniemi TH, Sotaniemi KA, Myllyla VV. Blood pressure and heart rate in parkinsonian patients with and without wearing-off. Eur J Neurol 2007; 14: 373–378.
- 111 Pursiainen V, Haapaniemi TH, Korpelainen JT, Sotaniemi KA, Myllyla VV. Sweating in Parkinsonian patients with wearing-off. Mov Disord 2007; 22: 828–832.
- 112 Baratti M, Calzetti S. Fluctuation of arterial blood pressure during end-of-dose akinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1984; 47: 1241–1243.
- 113 Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N. Sweating dysfunction in Parkinson's disease. Mov Disord 2003; 18: 1459–1463.
- 114 Raudino F. Non motor off in Parkinson's disease. Acta Neurol Scand 2001; 104: 312–315.
- 115 Quadri R, Comino I, Scarzella L, et al. Autonomic nervous function in de novo parkinsonian patients in basal condition and after acute levodopa administration. Funct Neurol 2000; 15: 81–86.
- 116 Muller B, Assmus J, Larsen JP, Haugarvoll K, Skeie GO, Tysnes OB. Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease. Acta Neurol Scand 2013; 127: 290–294.
- 117 Goldstein DS, Eldadah BA, Holmes C, et al. Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension 2005; 46: 1333–1339.
- 118 Kaufmann H, Goldstein DS. Autonomic dysfunction in Parkinson disease. Handb Clin Neurol 2013; 117: 259–278.
- 119 Uchiyama T, Sakakibara R, Hattori T, Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon. Mov Disord 2003; 18: 573–578.
- 120 Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson's disease: response to apomorphine. Ann Neurol 1993; 33: 490–493.
- 121 Snider SR, Fahn S, Isgreen WP, Cote LJ. Primary sensory symptoms in parkinsonism. Neurology 1976; 26: 423–429.
- 122 Hanagasi HA, Akat S, Gurvit H, Yazici J, Emre M. Pain is common in Parkinson's disease. Clin Neurol Neurosurg 2011; 113: 11–13.
- 123 Waseem S, Gwinn-Hardy K. Pain in Parkinson's disease. Common yet seldom recognized symptom is treatable. Postgrad Med 2001; 110: 33–4, 9–40, 46.
- 124 Rana AQ, Kabir A, Jesudasan M, Siddiqui I, Khondker S. Pain in Parkinson's disease: analysis and literature review. Clin Neurol Neurosurg 2013; 115: 2313–2317.
- 125 Silva EG, Viana MA, Quagliato EM. Pain in Parkinson's disease: analysis of 50 cases in a clinic of movement disorders. Arq Neuropsiquiatr 2008; 66: 26–29.
- 126 Zambito Marsala S, Tinazzi M, Vitaliani R, et al. Spontaneous pain, pain threshold, and pain tolerance in Parkinson's disease. J Neurol 2011; 258: 627–633.
- 127 Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord 2010; 25: 2493–2500.
- 128 Roh JH, Kim BJ, Jang JH, et al. The relationship of pain and health-related quality of life in Korean patients with Parkinson's disease. Acta Neurol Scand 2009; 119: 397–403.
- 129 Lefaucheur R, Berthelot L, Senant J, Borden A, Maltete D. Acute genital pain during non-motor fluctuations improved by apomorphine. Mov Disord 2013; 28: 687–688.
- 130 Rana AQ, Depradine J. Abdominal pain: a symptom of levodopa end of dose wearing off in Parkinson's disease. West Indian Med J 2011; 60: 223–224.
- 131 Quinn NP, Koller WC, Lang AE, Marsden CD. Painful Parkinson's disease. Lancet 1986; 1: 1366–1369.
- 132 Nebe A, Ebersbach G. Pain intensity on and off levodopa in patients with Parkinson's disease. Mov Disord 2009; 24: 1233–1237.
- 133 Ford B. Pain in Parkinson's disease. Mov Disord 2010; 25(Suppl 1): S98–S103.
- 134 Factor SA, Brown DL, Molho ES. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease. Mov Disord 2000; 15: 167–169.
- 135 Bayulkem K, Lopez G. Clinical approach to nonmotor sensory fluctuations in Parkinson's disease. J Neurol Sci 2011; 310: 82–85.
- 136 Juri C, Rodriguez-Oroz M, Obeso JA. The pathophysiological basis of sensory disturbances in Parkinson's disease. J Neurol Sci 2010; 289: 60–65.
- 137 Rijsman RM, Schoolderman LF, Rundervoort RS, Louter M. Restless legs syndrome in Parkinson's disease. Parkinsonism & related disorders 2014; 20(Suppl 1): S5–S9.
- 138 Tinazzi M, Recchia S, Simonetto S, et al. Muscular pain in Parkinson's disease and nociceptive processing assessed with CO2 laser-evoked potentials. Mov Disord 2010; 25: 213–220.
- 139 Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain 1995; 60: 3–38.
- 140 Prescott TJ, Montes Gonzalez FM, Gurney K, Humphries MD, Redgrave P. A robot model of the basal ganglia: behavior and intrinsic processing. Neural Netw 2006; 19: 31–61.
- 141 Brefel-Courbon C, Payoux P, Thalamas C, et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2005; 20: 1557–1563.
- 142 Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513–520.
- 143 Leeman AL, O'Neill CJ, Nicholson PW, et al. Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol 1987; 24: 637–643.
- 144 Ardouin C, Chereau I, Llorca PM, et al. [Assessment of hyper- and hypodopaminergic behaviors in Parkinson's disease]. Rev Neurol (Paris) 2009; 165: 845–856.
- 145 Kleiner-Fisman G, Martine R, Lang AE, Stern MB. Development of a non-motor fluctuation assessment instrument for Parkinson disease. Parkinsons Dis 2011; 2011: 292719.
- 146 Stacy M, Hauser R. Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease. J Neural Transm 2007; 114: 211–217.
- 147 Altavista MC, Cassetta E, Brusa L, et al. Wearing-off detection in clinical practice: the wearing off real practice key (WORK-PD) study in Parkinson's disease. Parkinsonism Relat Disord 2015; 21: 95–100.
- 148 Martinez-Martin P, Tolosa E, Hernandez B, Badia X. Validation of the “QUICK” questionnaire—a tool for diagnosis of “wearing-off” in patients with Parkinson's disease. Mov Disord 2008; 23: 830–836.
- 149 Stacy M, Hauser R, Oertel W, et al. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol 2006; 29: 312–321.
- 150 Martinez-Martin P, Hernandez B. The Q10 questionnaire for detection of wearing-off phenomena in Parkinson's disease. Parkinsonism Relat Disord 2012; 18: 382–385.
- 151 Antonini A, Martinez-Martin P, Chaudhuri RK, et al. Wearing-off scales in Parkinson's disease: critique and recommendations. Mov Disord 2011; 26: 2169–2175.
- 152 Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006; 21: 916–923.
- 153 Rieu I, Martinez-Martin P, Pereira B, et al. International validation of a behavioral scale in Parkinson's disease without dementia. Mov Disord 2015; 30: 705–713.
- 154 Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74: 924–931.
- 155 Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311: 1670–1683.
- 156 Witjas T, Kaphan E, Azulay JP. [Non-motor fluctuations in Parkinson's disease]. Rev Neurol (Paris) 2007; 163: 846–850.
- 157 Chaudhuri KR, Rizos A, Sethi KD. Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? J Neural Transm 2013; 120: 1305–1320.
- 158 Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013; 12: 346–356.
- 159 Odin P, Ray Chaudhuri K, Slevin JT, et al.; National Steering Committees. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. Parkinsonism Relat Disord 2015; 21: 1133–1144.
- 160 Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994; 44: 913–919.
- 161 Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947–954.
- 162 Calandrella D, Antonini A. Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. Parkinsonism Relat Disord 2012; 18(Suppl 1): S120–S122.
- 163 Smith KM, Eyal E, Weintraub D. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. JAMA Neurol 2015; 72: 88–95.
- 164 Kulisevsky J, Pascual-Sedano B, Barbanoj M, Gironell A, Pagonabarraga J, Garcia-Sanchez C. Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: a double-blind study. Mov Disord 2007; 22: 62–67.
- 165 Trenkwalder C, Kohnen R, Hogl B, et al. Parkinson's disease sleep scale—validation of the revised version PDSS-2. Mov Disord 2011; 26: 644–652.
- 166 Ray Chaudhuri K, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord 2013; 19: 660–665.
- 167 Kassubek J, Chaudhuri KR, Zesiewicz T, et al. Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study. BMC Neurol 2014; 14: 42.
- 168 Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Mov Disord 2014; 29: 1273–1280.
- 169 Pahwa R, Koller WC, Trosch RM, Sherry JH. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci 2007; 258: 137–143.
- 170 Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003; 2: 595–604.
- 171 Okai D, Askey-Jones S, Samuel M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 2013; 80: 792–799.
- 172 Calleo JS, Amspoker AB, Sarwar AI, et al. A pilot study of a cognitive-behavioral treatment for anxiety and depression in patients with Parkinson disease. J Geriatr Psychiatry Neurol 2015; 28: 210–217.
- 173 Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349: 1925–1934.
- 174 Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005; 20: 151–157.
- 175 Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009; 24: 993–1000.
- 176 Limousin P, Pollak P, Benazzouz A, et al. Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov Disord 1995; 10: 672–674.
- 177 Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 2008; 23: 1130–1136.
- 178 Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993; 8: 165–170.
- 179 Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002; 17: 1235–1241.
- 180 Todorova A, Ray Chaudhuri K. Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2013; 19: 1073–1078.
- 181 Martinez-Martin P, Reddy P, Antonini A, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis 2011; 1: 197–203.
- 182 Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord 2015; 30: 510–516.
- 183 Mathers SE, Kempster PA, Law PJ, et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 1989; 46: 1061–1064.
- 184 Christmas TJ, Kempster PA, Chapple CR, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988; 2: 1451–1453.
- 185 Dellapina E, Gerdelat-Mas A, Ory-Magne F, et al. Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2011; 26: 153–157.
- 186 Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease—long-term experience. Acta Neurol Scand 2001; 104: 343–348.
- 187 Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003; 26: 156–163.
- 188 Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with ‘on-off’ fluctuations. Neurology 1993; 43: 1698–1703.
- 189 Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014; 13: 141–149.
- 190 Caceres-Redondo MT, Carrillo F, Lama MJ, et al. Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease. J Neurol 2014; 261: 561–569.
- 191 Bellante F, Dethy S, Zegers de Beyl D. Depression, anxiety and non-motor symptoms on initiation of intrajejunal levodopa/carbidopa therapy. Acta Neurol Belg 201; 116: 39–41.
- 192 Antonini A, Yegin A, Preda C, Bergmann L, Poewe W. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord 2015; 21: 231–235.
- 193 Buongiorno M, Antonelli F, Cámara A, et al. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Parkinsonism Relat Disord 2015; 28: 871–876.
- 194 Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008; 31: 151–166.
- 195 Lhommee E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain 2012; 135: 1463–1477.
- 196 Lhommee E, Wojtecki L, Czernecki V, et al. EARLYSTIM: STN-DBS alleviates behavioural side effects of dopamine replacement therapy when compared to best medical treatment in a 2-year follow-up randomized controlled trial. Movement Disorders Society International Congress. Berlin: Movement disorders Society; 2016.
- 197 Funkiewiez A, Ardouin C, Krack P, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003; 18: 524–530.
- 198 Castrioto A, Lhommee E, Moro E, Krack P. Mood and behavioural effects of subthalamic stimulation in Parkinson's disease. Lancet Neurol 2014; 13: 287–305.
- 199 Castrioto A, Kistner A, Klinger H, et al. Psychostimulant effect of levodopa: reversing sensitisation is possible. J Neurol Neurosurg Psychiatry 2013; 84: 18–22.
- 200 Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896–908.
- 201 Funkiewiez A, Ardouin C, Caputo E, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 834–839.
- 202 Witt K, Daniels C, Herzog J, et al. Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2006; 18: 397–401.
- 203 Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008; 7: 605–614.
- 204 Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013; 368: 610–622.
- 205 Wolz M, Hauschild J, Koy J, et al. Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2012; 18: 994–997.
- 206 Bejjani BP, Damier P, Arnuslf I, et al. Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med 1999; 340: 1476–1480.
- 207 Strutt AM, Simpson R, Jankovic J, York MK. Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease. Eur J Neurol 2012; 19: 121–127.
- 208 Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010; 362: 2077–2091.
- 209 Antonini A, Yegin A, Preda C, et al. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord 2015; 21: 231–235.
- 210 Houeto JL, Mesnage V, Mallet L, et al. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72: 701–707.
- 211 Cury RG, Galhardoni R, Fonoff ET, et al. Effects of deep brain stimulation on pain and other nonmotor symptoms in Parkinson disease. Neurology 2014; 83: 1403–1409.
- 212 Czernecki V, Pillon B, Houeto JL, et al. Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease? J Neurol Neurosurg Psychiatry 2005; 76: 775–779.
- 213 Drapier D, Drapier S, Sauleau P, et al. Does subthalamic nucleus stimulation induce apathy in Parkinson's disease? J Neurol 2006; 253: 1083–1091.
- 214 Kirsch-Darrow L, Zahodne LB, Marsiske M, Okun MS, Foote KD, Bowers D. The trajectory of apathy after deep brain stimulation: from pre-surgery to 6 months post-surgery in Parkinson's disease. Parkinsonism Relat Disord 2011; 17: 182–188.
- 215 Bandini F, Primavera A, Pizzorno M, Cocito L. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord 2007; 13: 369–371.
- 216 Witjas T, Baunez C, Henry JM, et al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 2005; 20: 1052–1055.
- 217 Ardouin C, Voon V, Worbe Y, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006; 21: 1941–1946.
- 218 De la Casa-Fages B, Grandas F. Dopamine dysregulation syndrome after deep brain stimulation of the subthalamic nucleus in Parkinson's disease. J Neurol Sci 2012; 312: 191–193.
- 219 Eusebio A, Witjas T, Cohen J, et al. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease. J Neurol Neurosurg Psychiatry 2013; 84: 868–874.
- 220 Romito LM, Raja M, Daniele A, et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord 2002; 17: 1371–1374.
- 221 Ballanger B, van Eimeren T, Moro E, et al. Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol 2009; 66: 817–824.
- 222 Contarino MF, Daniele A, Sibilia AH, et al. Cognitive outcome 5 years after bilateral chronic stimulation of subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78: 248–252.
- 223 Halbig TD, Tse W, Frisina PG, et al. Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol 2009; 16: 493–497.
- 224 Lim SY, O'Sullivan SS, Kotschet K, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009; 16: 1148–1152.
- 225 Moum SJ, Price CC, Limotai N, et al. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One 2012; 7: e29768.
- 226 Todorova A, Samuel M, Brown RG, Chaudhuri KR. Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3 years' follow-up. Clin Neuropharmacol 2015; 38: 132–134.
- 227 Umemura A, Oka Y, Okita K, Matsukawa N, Yamada K. Subthalamic nucleus stimulation for Parkinson disease with severe medication-induced hallucinations or delusions. J Neurosurg 2011; 114: 1701–1705.
- 228 Stemper B, Beric A, Welsch G, Haendl T, Sterio D, Hilz MJ. Deep brain stimulation improves orthostatic regulation of patients with Parkinson disease. Neurology 2006; 67: 1781–1785.
- 229 Zibetti M, Torre E, Cinquepalmi A, et al. Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. Eur Neurol 2007; 58: 218–223.
- 230 Trachani E, Constantoyannis C, Sirrou V, Kefalopoulou Z, Markaki E, Chroni E. Effects of subthalamic nucleus deep brain stimulation on sweating function in Parkinson's disease. Clin Neurol Neurosurg 2010; 112: 213–217.
- 231 Winge K, Nielsen KK, Stimpel H, Lokkegaard A, Jensen SR, Werdelin L. Lower urinary tract symptoms and bladder control in advanced Parkinson's disease: effects of deep brain stimulation in the subthalamic nucleus. Mov Disord 2007; 22: 220–225.
- 232 Seif C, Herzog J, van der Horst C, et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol 2004; 55: 118–120.
- 233 Finazzi-Agro E, Peppe A, D'Amico A, et al. Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson's disease. J Urol 2003; 169: 1388–1391.
- 234 Shimizu N, Matsumoto S, Mori Y, et al. [Effects of deep brain stimulation on urodynamic findings in patients with Parkinson's disease]. Hinyokika Kiyo 2007; 53: 609–612.
- 235 Herzog J, Weiss PH, Assmus A, et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson's disease. Brain 2006; 129: 3366–3375.
- 236 Ciucci MR, Barkmeier-Kraemer JM, Sherman SJ. Subthalamic nucleus deep brain stimulation improves deglutition in Parkinson's disease. Mov Disord 2008; 23: 676–683.
- 237 Kulneff L, Sundstedt S, Olofsson K, et al. Deep brain stimulation—effects on swallowing function in Parkinson's disease. Acta Neurol Scand 2013; 127: 329–336.
- 238 Hariz MI, Rehncrona S, Quinn NP, Speelman JD, Wensing C. Multicenter study on deep brain stimulation in Parkinson's disease: an independent assessment of reported adverse events at 4 years. Mov Disord 2008; 23: 416–421.
- 239 Castelli L, Perozzo P, Genesia ML, et al. Sexual well being in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2004; 75: 1260–1264.
- 240 Kim HJ, Paek SH, Kim JY, et al. Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. J Neurol 2008; 255: 1889–1894.
- 241 Gierthmuhlen J, Arning P, Binder A, et al. Influence of deep brain stimulation and levodopa on sensory signs in Parkinson's disease. Mov Disord 2010; 25: 1195–1202.
- 242 Surucu O, Baumann-Vogel H, Uhl M, Imbach LL, Baumann CR. Subthalamic deep brain stimulation versus best medical therapy for L-dopa responsive pain in Parkinson's disease. Pain 2013; 154: 1477–1479.
- 243 Loher TJ, Burgunder JM, Weber S, Sommerhalder R, Krauss JK. Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 395–399.
- 244 Driver-Dunckley E, Evidente VG, Adler CH, et al. Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation. Mov Disord 2006; 21: 1287–1289.
- 245 Chahine LM, Ahmed A, Sun Z. Effects of STN DBS for Parkinson's disease on restless legs syndrome and other sleep-related measures. Parkinsonism Relat Disord 2011; 17: 208–211.
- 246 Kedia S, Moro E, Tagliati M, Lang AE, Kumar R. Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. Neurology 2004; 63: 2410–2412.